Dr. Boccia on Managing Adverse Events With CAR T-Cell Therapy

Ralph Boccia, MD
Published: Friday, Nov 16, 2018



Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events (AEs) associated with chimeric antigen receptor (CAR) T-cell therapy.

CAR T-cell therapy has been a game changer in terms of treating various types of leukemia, but it does have some AEs, such as cytokine release syndrome (CRS). Oncologists are developing strategies to mitigate those effects. Oncologists learned early about CRS with CAR T-therapy that could result in toxicity and neurologic problems. There are keys or clues to the development of CRS, namely, fever, says Boccia. One way oncologists have been able to mitigate this is to recognize CRS early and get the patient started on tocilizumab (Actemra), which would block some of the effects.

Oncologists also have a strategy of grading the degree of CRS and knowing exactly when to implement that drug that would block AEs.
SELECTED
LANGUAGE


Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events (AEs) associated with chimeric antigen receptor (CAR) T-cell therapy.

CAR T-cell therapy has been a game changer in terms of treating various types of leukemia, but it does have some AEs, such as cytokine release syndrome (CRS). Oncologists are developing strategies to mitigate those effects. Oncologists learned early about CRS with CAR T-therapy that could result in toxicity and neurologic problems. There are keys or clues to the development of CRS, namely, fever, says Boccia. One way oncologists have been able to mitigate this is to recognize CRS early and get the patient started on tocilizumab (Actemra), which would block some of the effects.

Oncologists also have a strategy of grading the degree of CRS and knowing exactly when to implement that drug that would block AEs.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x